Transcend Medical says it closed on a $22 million Series C round, including an investment from an unnamed medical device multi-national.
Transcend Medical said it closed on a Series C round worth $22 million that included a contribution from an unnamed "global pharmaceutical and medical device company."
Transcend, which is developing a micro-stent called the CyPass to treat glaucoma, said it plans to use the proceeds to complete its Compass pivotal trial for the CyPass device. The study's follow-up period is slated to be complete during the 2nd quarter of 2015, according to a press release.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1h3b4XU
Cap comentari:
Publica un comentari a l'entrada